Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan : Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America..
BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant.
METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed.
RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged ≥65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months.
CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
---|---|
Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 75(2022), 11 vom: 30. Nov., Seite 1971-1979 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Maeda, Haruka [VerfasserIn] |
---|
Links: |
---|
Themen: |
BNT162 Vaccine |
---|
Anmerkungen: |
Date Completed 02.12.2022 Date Revised 15.01.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/cid/ciac292 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM339675039 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM339675039 | ||
003 | DE-627 | ||
005 | 20231226003428.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/cid/ciac292 |2 doi | |
028 | 5 | 2 | |a pubmed24n1132.xml |
035 | |a (DE-627)NLM339675039 | ||
035 | |a (NLM)35438137 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Maeda, Haruka |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan |b Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.12.2022 | ||
500 | |a Date Revised 15.01.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. | ||
520 | |a BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant | ||
520 | |a METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed | ||
520 | |a RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged ≥65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months | ||
520 | |a CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Delta | |
650 | 4 | |a Japan | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a vaccine effectiveness | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a RNA, Messenger |2 NLM | |
650 | 7 | |a BNT162 Vaccine |2 NLM | |
700 | 1 | |a Saito, Nobuo |e verfasserin |4 aut | |
700 | 1 | |a Igarashi, Ataru |e verfasserin |4 aut | |
700 | 1 | |a Ishida, Masayuki |e verfasserin |4 aut | |
700 | 1 | |a Suami, Kazuya |e verfasserin |4 aut | |
700 | 1 | |a Yagiuchi, Ai |e verfasserin |4 aut | |
700 | 1 | |a Kimura, Yuya |e verfasserin |4 aut | |
700 | 1 | |a Komino, Masaru |e verfasserin |4 aut | |
700 | 1 | |a Arai, Hiromi |e verfasserin |4 aut | |
700 | 1 | |a Morikawa, Toru |e verfasserin |4 aut | |
700 | 1 | |a Motohashi, Iori |e verfasserin |4 aut | |
700 | 1 | |a Miyazawa, Rei |e verfasserin |4 aut | |
700 | 1 | |a Moriyama, Tetsu |e verfasserin |4 aut | |
700 | 1 | |a Kamura, Hiroshi |e verfasserin |4 aut | |
700 | 1 | |a Terada, Mayumi |e verfasserin |4 aut | |
700 | 1 | |a Kuwamitsu, Osamu |e verfasserin |4 aut | |
700 | 1 | |a Hayakawa, Tomoichiro |e verfasserin |4 aut | |
700 | 1 | |a Sando, Eiichiro |e verfasserin |4 aut | |
700 | 1 | |a Ohara, Yasuji |e verfasserin |4 aut | |
700 | 1 | |a Teshigahara, Osamu |e verfasserin |4 aut | |
700 | 1 | |a Suzuki, Motoi |e verfasserin |4 aut | |
700 | 1 | |a Morimoto, Konosuke |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 75(2022), 11 vom: 30. Nov., Seite 1971-1979 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
773 | 1 | 8 | |g volume:75 |g year:2022 |g number:11 |g day:30 |g month:11 |g pages:1971-1979 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac292 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 75 |j 2022 |e 11 |b 30 |c 11 |h 1971-1979 |